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Abstract
Background: Pancreatic cancer is the 4th leading cause of death from cancer in the U.S. The
opioid growth factor (OGF; [Met5]-enkephalin) and the OGF receptor form an inhibitory growth
regulatory system involved in the pathogenesis and treatment of pancreatic cancer. The OGF-
OGFr axis influences the G0/G1 phase of the cell cycle. In this investigation, we elucidate the
pathway of OGF in the cell cycle.
Results: Using BxPC-3 cells, OGF decreased phosphorylation of retinoblastoma (Rb) protein
without changing total Rb. This change was correlated with reduced cyclin-dependent kinase
protein (Cdk) 2 kinase activity, but not total Cdk2. OGF treatment increased cyclin-dependent
kinase inhibitor (CKI) p21 protein expression in comparison to controls, as well levels of p21
complexed with Cdk2. Naloxone abolished the increased expression of p21 protein by OGF,
suggesting a receptor-mediated activity. p21 specific siRNAs blocked OGF's repressive action on
proliferation in BxPC-3, PANC-1, and Capan-2 cells; cells transfected with negative control siRNA
had no alteration in p21 expression, and therefore were inhibited by OGF.
Conclusion: These data are the first to reveal that the target of cell proliferative inhibitory action
of OGF in human pancreatic cancer is a p21 CKI pathway, expanding strategies for diagnosis and
treatment of these neoplasias.
Background
The opioid growth factor (OGF), chemically termed
[Met5]-enkephalin, is an endogenous opioid peptide that
is an important regulator of the progression of human
pancreatic cancer [1-3]. OGF is a constitutively expressed
native opioid that is autocrine produced and secreted, and
interacts with the OGF receptor (OGFr) to inhibit the
growth of pancreatic cancer cells in vitro and in tumor
xenografts [2,3]. The action of OGF is tonic, stereospecific,
reversible, non-cytotoxic and non-apoptotic inducing, not
associated with differentiative, migratory, invasive, or
adhesive processes, independent of serum, anchorage-
independent, and occurs at physiologically relevant con-
centrations in a wide variety of pancreatic cancers includ-
ing poorly- and well-differentiated human cell lines [1-3].
The only opioid peptide, natural or synthetic, that influ-
ences the growth of pancreatic cancer is OGF [2]. The
action of this opioid in these neoplasias is targeted to
DNA synthesis [4] and is directed toward the G0/G1 inter-
face of the cell cycle [5]. Exogenous administration of
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OGF has a profound antitumor action on xenografts of
pancreatic cancer that includes delaying tumor appear-
ance and reducing tumor size [6]. The combination of
biotherapy with OGF and chemotherapy with gemcitab-
ine has proven to enhance antitumor effectiveness beyond
either agent alone [6]. OGF has been successful in Phase 1
clinical trials [7].
The gene for human OGFr is at least 9 kb in length, con-
sists of seven exons and six introns, and encodes a 677
amino acid protein that includes 7 imperfect repeats of 20
amino acids each and a bipartite nuclear localization sig-
nal [1]. OGFr has an apparent mass of 62 kDa. The chro-
mosomal location of the human OGFr is 20q13.3 [1].
Although OGFr has characteristics of a classical opioid
receptor (recognizes opioids, naloxone reversibility, stere-
ospecificity), there is no homology of OGFr with classical
opioid receptors in terms of nucleotides or amino acids
[1]. Antisense experiments with OGFr and continuous
blockade of opioid receptors by the potent opioid antag-
onist naltrexone (NTX) support that the OGF-OGFr axis is
a tonically active inhibitory system targeted to cell replica-
tion and homeostasis, and is ligand-dependent for func-
tion [1]. Immunoelectron and confocal microscopy have
shown that OGFr is localized to the outer nuclear enve-
lope, nucleus, and perinuclear cytoplasm [8]. Gene
expression [1], and protein expression [1] of OGFr, as well
as binding activity [1] have been identified and character-
ized in pancreatic cancer cell lines revealing the autocrine
nature of this growth regulatory axis.
The action of OGF in neoplasias is targeted to DNA syn-
thesis [4] and, in the cases of pancreatic, squamous cell
carcinoma of the head and neck (SCCHN), and colon can-
cer, is directed toward the G0/G1 interface of the cell cycle
[5]. Further study in SCCHN has revealed that the p16 cyc-
lin dependent inhibitory kinase pathway is the target of
OGF [9]. However, the total frequency of mutations and
of homozygous deletions involving the p16 gene in
human pancreatic carcinoma is nearly 80% [10,11]. Since
OGF depresses DNA synthesis and subsequent cell/tissue
growth in human pancreatic cancer cells in vitro and in
xenografts transplanted into nude mice [3], and flow
cytometry studies indicate that the Go/G1 of the cell cycle
is altered [5], the question arises as to the mechanism of
peptide action on the cell cycle in cancers that have a
mutation/deletion of p16. The present investigation
examined the specific target(s) in the cell cycle for the
OGF-OGFr axis in pancreatic cancers that contain a muta-
tion/deletion of p16.
Results
OGF inhibits cell proliferation and retards progression 
through the cell cycle
Continuous exposure to exogenous OGF inhibited the
growth of BxPC-3 human pancreatic cancer cells. At 48
and 72 hours, cell number in the OGF-treated wells was
66% and 55%, respectively, compared to control cultures
receiving sterile water (Fig. 1A). Linear regression analysis
of the data revealed mean doubling times for the OGF and
control groups of approximately 51.0 and 28.6 hours,
respectively; these doubling times differed from each
other at p < 0.01.
To examine the specificity of OGF for OGFr, knockdown
experiments with OGFr-siRNA were conducted (Fig. 1B).
Exposure to 10-6 M OGF depressed the growth of wt and
control siRNA-treated cells by 31% and 27%, respectively,
whereas 10-6 M NTX increased the number of both wt and
control siRNA-exposed cells by 19%. BxPC-3 cells sub-
jected to OGFr-siRNA had approximately 41% more cells
than wt cultures, and 38% more cells than control siRNA-
treated cultures. In contrast to cells expressing OGFr,
exposure to 10-6 M OGF or NTX had no further effects on
the OGFr-siRNA cultures.
Based on growth curves, the effect of OGF on cell cycle dis-
tribution by flow cytometry was analyzed (Fig. 1B). The
percentage of OGF-treated cells in the G0/G1 phase was
69.1% compared to 55.1% of the control cells (Fig. 1C).
Correspondingly, the number of OGF-exposed cells in S
phase decreased to 28.0% relative to 44.8% of the sterile
water control cells (Fig. 1B). The number of cells subjected
to OGF in the G2/M phase was 2.9% in relationship to
0.1% for control samples.
OGF treatment does not change total Rb protein but 
decreases the amount of phosphorylated Rb
The phosphorylation of Rb protein is necessary for cells to
progress from G1 to the S phase. To elucidate the role of
Rb in OGF-induced BxPC-3 cell growth inhibition, Rb
expression and the phosphorylated state of Rb were
assessed in synchronized BxPC-3 cells. Expression of total
Rb protein was not decreased from baseline values after
21 hours of OGF treatment using an antibody at 1:200
dilution. However, the level of phospho-Rb (Ser795),
which is specifically phosphorylated by Cdk2/4 in the G1
phase [12], was decreased at 15, 18, and 21 hours follow-
ing exposure to 10-6 M OGF, and reached statistical signif-
icance at 21 hours (p < 0.01) (Figs. 2A, B). Although
phospho-Rb (pSer807/811) was specifically phosphor-
ylated by Cdk4 in the G1 phase [12], OGF treatment did
not alter the results of Western blot analysis of phospho-
Rb (pSer807/811) levels (Fig. 2B). These results suggest
that Cdk2, not Cdk4, was involved in the OGF-induced
cell cycle block at the G1 phase in BxPC-3 cells.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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OGF inhibits BxPC-3 growth by arresting cells in G1 Figure 1
OGF inhibits BxPC-3 growth by arresting cells in G1. (A) BxPC-3 cells were grown in the presence of 10-6 M OGF for 72 
hours, and counted after 24, 48, or 72 hours of treatment. The number of cells in OGF-treated cultures were significantly 
reduced from control cultures receiving sterile water at 48 (***p < 0.001) and 72 (**p < 0.01) hours. Cells grown in the pres-
ence of the long-acting and potent general opioid antagonist naltrexone (NTX), which blocks the OGF-OGFr axis, enhances 
cell proliferation. (B) OGFr is required for OGF action on growth. BxPC-3 cells were transfected with OGFr siRNAs or con-
trol siRNAs for 24 hours in the presence of 10-6 M OGF, 10-6 M NTX, or sterile water. Cells were harvested at 96 hours and 
counted with a hemacytometer. Data represent means ± SE for 2 independent experiments. Cell numbers differed from wt or 
Ctrl siRNA cultures treated with sterile water at p < 0.001 (***). (C) Flow cytometry of synchronized BxPC-3 cells subjected 
to sterile water (control) or OGF for 21 hours as determined by FACS analysis. (D) Mean percentage of cells in G1, S, and G2 
phases. The percentage of OGF-treated cells in G1 was significantly elevated from control values at ***p < 0.001.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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Inhibition of Rb phosphorylation and Cdk2 kinase activity by OGF Figure 2
Inhibition of Rb phosphorylation and Cdk2 kinase activity by OGF. (A) Synchronized BxPC-3 cells were grown in the presence 
of OGF or sterile water and harvested at 15, 18 and 21 hours. Equal amounts of protein were analyzed by Western blot using 
specific antibodies recognizing phosphorylated Rb (Ser807/811 or Ser795), and normalized to actin. (B) Densitometric analysis 
of Western blots in (A). Rb phosphorylation after OGF treatment is expressed relative to controls at the respective time 
point. Cdk2 activity as detected by phosphorylation on Rb Ser795 antibodies was reduced approximately 2-fold in OGF-
treated groups relative to controls at all time points, and was significantly repressed at 21 hours (**p < 0.01). The lower level 
of phosphorylation at early time points resulted in higher variability due to quantifying low signals; as a consequence, the early 
time points are not statistically significant, but nevertheless the trend is clearly similar. No significant change in Rb phorphoryla-
tion related to Cdk4 kinase activity as assessed by phosphorylation at SER807/811 was recorded at any time point. Absolute 
changes in phosphorylation were less than 48%. (C) Cdk2 kinase activity was evaluated in synchronized BxPC-3 cells treated 
with OGF for 15, 18 or 21 hours. Cdk2 kinase activity was measured as the capacity of phosphorylation of H1 protein in the 
presence of radioactive ATP. Densitometric analysis of the kinase assay was performed, and the Cdk2 activity was measured 
relative to controls. Values represent means ± SE for 3 independent experiments. Kinase activity values from OGF-treated cul-
tures were significantly reduced from control cells at each respective time point (*p < 0.05, **p < 0.01, ***p < 0.001).Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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OGF reduces Cdk2 kinase activity
To verify whether the OGF-induced downregulation of
pRb was associated with changes in Cdk2, Cdk2 expres-
sion and activity levels were determined. The expression
of Cdk2 protein did not change following OGF exposure
(Fig. 2C). When H1 was used as substrate in immunopre-
cipitation experiments performed with antibodies against
Cdk2, lysates from cells treated with OGF for 15, 18 and
21 hours showed a significant decrease of 78%, 46% and
82%, respectively, in kinase activities compared to sterile
water treated control cultures (Fig. 2C). These results dem-
onstrate that the OGF-mediated decrease of pRb was con-
sistent with the reduction in Cdk2 kinase activities.
OGF does not affect the cyclin E/Cdk2 complex
To examine whether the OGF-induced downregulation of
Cdk2 kinase activity was related to a change in cyclin E
expression, homogenates of BxPC-3 cells were subjected
to Cdk2 immunoprecipitation. Cyclin E protein levels
were assessed by Western blotting. The level of the cyclin
E/Cdk2 complex after treatment with OGF revealed no
change from control levels [Additional file 1].
p21 expression is upregulated by OGF in a receptor 
mediated manner
Cell cycle progression depends on both positive and neg-
ative regulators. Expression of p21 was evaluated in syn-
chronized BxPC-3 cells after 3, 6, 9, and 12 hours of OGF
exposure. p21 was significantly upregulated (p < 0.05) in
OGF-treated cells relative to sterile water control cells after
9 hours of drug treatment (Fig. 3A).
Because p21 inhibits Cdk2 by physical interaction, we
examined whether the OGF-induced downregulation of
Cdk2 kinase activity was based on p21/Cdk2 complex for-
mation. To explore this possibility, homogenates of BxPC-
3 cells were subjected to Cdk2 immunoprecipitation, and
the precipitated proteins were probed with p21 antibod-
ies. The level of the p21/Cdk2 complex following OGF
treatment was elevated at all time points compared to
control levels, and reached statistical significance (p <
0.05) at 15 hours (Fig. 3B).
To demonstrate the opioid-receptor mediation of OGF,
cells were treated concomitantly with the opioid antago-
nist naloxone and OGF. OGF-induced upregulation of
p21 expression was blocked in cells exposed to both
naloxone and OGF; naloxone alone had no effect on p21
expression (Fig. 3C). This result showed that OGF-
induced upregulation of p21 expression was receptor
mediated. p21 is known as a tumor suppressor gene, func-
tioning as a cell cycle inhibitor by forming heterotrimeric
complexes with Cdks and cyclins. Therefore, the data sug-
gest that under the effect of OGF, p21 protein levels were
upregulated, and activated the p21-Rb pathway that, in
turn, mediated the cell cycle blockade.
Analysis of the expression of the cell cycle inhibitor p27
revealed that OGF treatment had no significant effect on
expression levels of this CKI (Fig. 4). p57 protein was not
detected on Western blots (1:200 dilution) of BxPC-3
cells. Thus, OGF-treatment results in the induction of only
p21 in pancreatic cancer.
Transfection with siRNAs directed against p21 blocks OGF 
inhibitory action
To test the role of p21 in OGF-induced inhibitory action
on BxPC-3 cell growth, siRNA knockdown experiments
were utilized. BxPC-3 cells were treated with p21 siRNA or
with negative control siRNA. As revealed by Western blot
analysis, the p21 siRNA efficiently reduced the level of
p21 protein compared to control cells at 48, 72, 96, and
120 hours (Fig. 5A). Growth analysis of cells transfected
with p21 siRNAs and subsequently exposed to OGF for
120 hours, showed that p21 induction is required for the
OGF inhibitory action on BxPC-3 cell growth (Fig. 5B).
BxPC-3 cells transfected with the negative control siRNAs
and exposed to OGF exhibited significant reductions in
growth of 17.8%, 28.6%, 35.8%, and 33.0% at 48, 72, 96,
and 120 hours, respectively.
To examine the ubiquity of the integral role of p21 as a
cyclin-dependent kinase inhibitor, two other human pan-
creatic cancer cell lines were examined: PANC-1 and
Capan-2. In synchronized PANC-1 cells, OGF increased
p21 expression at 6 hours relative to control cells. Western
blot analysis of protein isolated from these cells trans-
fected with p21 siRNA revealed a 51% reduction in p21
levels in comparison to control cells at 96 hours. Growth
curves indicated that OGF had no inhibitory effect on
PANC-1 cells lacking p21, but OGF exposure markedly
decreased growth by 34.1% at 72 hours and 35.5% at 96
hours in cells transfected with the negative control siRNAs
compared to cultures treated with sterile water (Fig. 5C).
In Capan-2 cells, OGF increased p21 expression at 3 hours
relative to control cultures. Capan-2 cells transfected with
p21 siRNA had 60% of p21 relative to control cells at 72
hours. Growth curves revealed that OGF had no inhibi-
tory action on Capan-2 cells lacking p21, but OGF did
depress growth of Capan-2 cells transfected with negative
control siRNA at 48, 72, and 96 hours (Fig. 5D).
Discussion
The OGF-OGFr axis has been documented by structural,
pharmacological, and biochemical evidence to be present
and to function as a regulatory system for growth in
human pancreatic cancer. First, OGF and OGFr have been
identified in human pancreatic cancer cell lines and
tumor tissues by immunohistochemistry [2,3]. Second,Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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OGF induced p21 expression Figure 3
OGF induced p21 expression. (A) BxPC-3 cells were synchronized by nocodazole (67 ng/ml) for 24 hours, and subsequently 
treated with 10-6 M OGF or sterile water for 3, 6, 9, 12, 15, 18, and 21 hours. Total proteins were resolved by SDS-PAGE, and 
blotted with p21 specific antibodies. Densitometric analysis of the Western blots was performed, and p21 expression for 
OGF-treated cells is expressed relative to controls at each time point. The p21 level was significantly (*p < 0.05) elevated from 
the control group at 9 hours. (B) To examine whether the OGF-induced downregulation of Cdk2 kinase activity was based on 
p21/Cdk2 complex formation, homogenates of BxPC-3 cells treated with OGF or sterile water were subjected to Cdk2 immu-
noprecipitation; the resulting proteins were blotted with antibodies to p21. Densitometric analysis of Western blots of immu-
noprecipitated p21/Cdk2 complexed protein at 3, 6, 9, 12, 15, 18, and 21 hours revealed an increase at 9, 12, 15, 18, and 21 
hours, with significant difference between the OGF and 15-hour control group (*p < 0.05). (C) Opioid receptor mediation of 
OGF action was evaluated in synchronized BxPC-3 cells treated with 10-6 M OGF, 10-5 M naloxone (NAL), both OGF and 
NAL, or sterile water (Control) for 9 hours. Protein lysates were resolved on SDS-PAGE, and subjected to Western blot anal-
ysis for p21 and actin. Densitometric analysis of p21 expression showed that p21 levels of OGF -treated cells were significantly 
elevated from controls at *p < 0.05; no change was recorded in the NAL and OGF-NAL groups. Data represent means ± SE 
for 3 independent experiments.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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OGFr has been characterized in human pancreatic cancer
cells and surgical specimens by receptor binding [13,14],
and shown to have at least a 10-fold greater affinity for
OGFr than any other natural or synthetic opioid peptide
(including those specific for μ, δ, or κ classical opioid
receptors) [13]. Third, exogenous OGF depresses the pro-
liferation of human pancreatic cancer cells in vitro [2,5,6]
and in xenografts [3,6], and elimination of endogenous
OGF neutralizes this peptide's action on cell replication
[2]. However, these previous studies do not directly dem-
onstrate that OGF, which also recognizes other classical
opioid receptors [15], also may elicit naloxone-sensitive
anti-proliferative signaling through these receptors
instead of or in addition to OGFr. The logical extension of
this query is that the effects of OGF on the cell cycle may
be related to OGFr and/or other opioid receptors. Using
OGFr knockdown experiments, the present report now
shows, for the first time, that the specific and singular
receptor for OGF action on the replication of a human
pancreatic cancer cell line is OGFr. Cells with silenced
OGFr are not altered by addition of OGF.
Moreover, these cells with a knockdown of OGFr are not
influenced by NTX, documenting that other opioid recep-
tors are not involved with the effects of this general opioid
receptor antagonist. Thus, the elucidation of the target of
OGF in this study is directly – and solely – related to
OGFr.
This study shows for the first time that the target of the
negative growth regulator, OGF is the cyclin-dependent
kinase inhibitor p21. Using a human pancreatic cancer
cell line, BxPC-3, that exhibited growth inhibition follow-
ing exposure to OGF, and flow cytometry observations
documenting that OGF impeded cells exiting Go/G1, we
now conclude that the peptide action is related to a key
regulator of the G1 to S phase transition – the tumor sup-
pressor Rb protein. This would suggest that OGF action in
regard to the cell cycle is not broad based, but rather
extremely specific to a pathway focused on the phosphor-
ylation of Rb. The effects of OGF on p21 were found to be
receptor mediated, as concomitant exposure to the opioid
antagonist naloxone blocked the up-regulation of p21 by
OGF; naloxone treatment alone had no effect on p21 lev-
els, indicating that there was not simply a counterbalance
of up- and down-regulation between OGF and naloxone.
Finally, confirmation that p21 was indeed the target of
OGF was validated in siRNA studies whereby pancreatic
cancer cells exposed to p21 siRNA exhibited no change in
growth after exposure to OGF. Thus, our study makes the
novel finding that OGF is directed to a singular compo-
nent of the cell cycle.
This investigation also shows that the action of OGF on
the p21 cyclin-dependent inhibitory kinase in pancreatic
cancer is not specific to the BxPC-3 cell line, but that the
p21-Rb pathway is present and active in a number of other
pancreatic cancer cell lines. Thus, two other cell lines
exhibiting different levels of differentiation and origin,
PANC-1 and Capan-2 cell lines demonstrated that the p21
pathway was targeted by OGF as well. Capan-2 was
derived from a well-differentiated adenocarcinoma in the
head of the pancreas of a 56-year old male [16], BxPC-3
originated from the body and tail of the pancreas of a 61-
year old female and was characterized as a moderately
well to poorly differentiated adenocarcinoma [17]
whereas PANC-1 was an undifferentiated adenocarci-
noma derived from the head of the pancreas from a 56-
year old male [18]. Thus, OGF appears to act on the p21
pathway in a variety of human pancreatic cancer cell lines,
suggesting that this may be the primary pathway of cell
cycle influence of the OGF-OGFr axis in these cancers.
Whether OGF also influences p21 in vivo in humans is
unclear and requires further study.
OGF has no effect on CKI p27 expression Figure 4
OGF has no effect on CKI p27 expression. BxPC-3 cells 
were synchronized by nocodazole (67 ng/ml) for 24 hours, 
and subsequently treated with 10-6 M OGF for 3, 6, 9, 12, 15, 
18, or 21 hours. (A) Total protein lysates were resolved by 
SDS-PAGE and subjected to antibodies specific to p27. (B) 
Densitometic analysis revealed changes in p27 expression of 
less than 38% between OGF and sterile water treated values; 
none of these changes were statistically significant.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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p21 is required for OGF-induced growth inhibition Figure 5
p21 is required for OGF-induced growth inhibition. (A) BxPC-3 cells were transfected with p21 siRNAs or negative control 
siRNAs for 48, 72, 96, or 120 hours. Total proteins were isolated and separated by SDS-PAGE, and probed with antibodies 
specific to p21. (B-D) Growth curves for BxPC-3 (B), PANC-1 (C) and Capan-2 (D) cells transfected with either p21 siRNA or 
negative control siRNA, and grown in the presence or absence of 10-6 M OGF for 96 or 120 hours. Cells were harvested at 48, 
72, 96 or 120 hours, and counted with a hemacytometer. Data represent means ± SE for 3 independent experiments. OGF had 
no effect on cell growth of any cell line transfected with p21 siRNA. Cell numbers for OGF-treated cultures transfected with 
negative control siRNA were significantly reduced from transfected cells receiving sterile water at *p < 0.05, **p < 0.01, or 
***p < 0.001.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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During the cell cycle progression, Rb is sequentially phos-
phorylated by different cyclin/Cdk complexes [12]. Differ-
ent phosphorylation sites in Rb have been demonstrated,
with the preferred site being S807/811 by Cdk4/cyclin D and
S795 by Cdk2/4 [12]. Our observation that OGF down-reg-
ulated the phosphorylation of Rb on S795 is consistent
with decreased Cdk2 kinase activity. Cdk2 activity was
decreased relative to controls at 15, 18, and 21 hours in
response to OGF treatment. This reduction in Cdk2 kinase
activity correlated with an increase in Cdk2/p21 complex
formation in the OGF-exposed cells relative to control cul-
tures at all time points. We also observed that OGF had no
effect on Rb S807/811 phosphorylation, which implies that
OGF did not affect Cdk4 activity. Thus, OGF exerts its
effects in these cancer cells by inducing Cdk2/p21 com-
plexes.
p21 has been considered as a target for potential antican-
cer drugs [19,20]. For example, using recombinant aden-
oviral system (rAd-p21), Joshi et al.[19] found the growth
of two pancreatic tumor cell lines can be inhibited by p21
in vitro, with significant numbers of tumor cells reverting
from S to Go/G1. Studies also showed that TGF-β induced
p21waf1 expression in PANC-1 cells, along with subse-
quent growth inhibition [21]. Our studies in this report
suggest that OGF inhibited cell growth by upregulating
p21 expression. However, in the case of pancreatic cancer,
these changes are transient, indicating that OGF has a
cytostatic but not cytotoxic effects. These observations
may explain why OGF has no effect on apoptosis and
necrosis [22,23].
This study was prompted by gaining an understanding of
the nature of OGF's inhibitory influence on the cell cycle.
A previous report in SCCHN has shown that OGF is tar-
geted to the p16 cyclin-dependent kinase inhibitory path-
way [9]. However, human pancreatic cancers exhibit
mutations of the p16 gene in 80% or more of the cases
examined [10,11]. The present study utilized human pan-
creatic tumor cell lines that have mutations of the p16
gene [24] in order to reproduce a model of surgical speci-
mens. The results show that another CKI, p21, is the target
of OGF activity. This novel finding indicates that the CKI
pathways are malleable to the OGF-OGFr axis, and can
accommodate to changes in gene changes. These data also
demonstrate that OGF is dependent CKIs to transmit their
inhibitory influence on growth. Whether other CKIs can
mediate the effects of OGF in the face of mutations of p16
and p21 remains to be determined. Moreover, the CKIs
involved with the modulatory action of the OGF-OGFr
system in normal cells require clarification.
The clinical ramifications of our findings merit further dis-
cussion. A review of the literature indicates that most pan-
creatic cancers resected in patients contain p21, hence our
selection of pancreatic cancer cell lines that were known
to have p21. For example, Biankin et al.[25] examined the
protein expression of p21 in 125 patients and they found
that 79% of the tumors were positive for p21. Ahrendt et
al.[26] recorded p21 protein expression in 56% of the 90
patients with pancreatic cancer, and reported a longer sur-
vival in these patients taking chemotherapy [26]. There-
fore, neoplasias with the p21 pathway would be predicted
to react positively to OGF therapy. Whether they use a dif-
ferent cyclin-dependent inhibitory kinase pathway needs
to be determined.
Conclusion
These data are the first to reveal that the target of cell pro-
liferative inhibitory action of OGF in human pancreatic
cancer is a p21 CKI pathway, expanding strategies for
diagnosis and treatment of these neoplasias
Methods
Cell culture and OGF treatment
Human pancreatic cancer cell lines BxPC-3, PANC-1, and
Capan-2 were obtained from the American Type Culture
Collection (Manassas, VA), and cultured in RPMI, Del-
becco's Modified Medium, or McCoy's 5A medium,
respectively. All media was supplemented with 10% FBS,
1.2% sodium bicarbonate, and 0.25% antibiotics (5000
units/ml penicillin, 5 μg/ml streptomycin and 10 μg/ml
neomycin).
OGF was purchased from Sigma-Aldrich (St. Louis, MO),
dissolved in sterile water, and used at a final concentra-
tion of 10-6 M.
Cell growth and flow cytometry
For growth curves, cells were seeded in 6-well plates at an
initial density of ~2 × 105 cells/well. Fresh media and OGF
were added 24 hours after initial seeding, and media and
OGF were replaced daily. At appropriate times, the cells
were washed with PBS, trypsinized, and viable cell num-
bers were counted by trypan blue exclusion using a hem-
acytometer.
For flow cytometry, cells were synchronized with 67 ng/
ml nocodazole (Sigma-Aldrich) for 24 hours, followed by
three washes with complete media. Cells were released
from growth arrest by addition of complete media or
OGF-supplemented media. Synchronized cells were
treated with 10-6 M OGF for 21 hours; this dosage of OGF
was selected because it significantly inhibits cell replica-
tion of BxPC-3, PANC-1, Capan-1, and MIA PaCa-2
human pancreatic cells [2] and does not induce apoptosis
or necrosis [22] or differentiation [23]. Cells were, har-
vested with 0.25% trypsin-EDTA (Mediatech, Herndon,
VA) and fixed with 70% ethanol at -20°C for up to 7 days
before DNA analysis. DNA content was obtained by incu-Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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bating cells in PBS containing propidium iodide (0.1 mg/
ml) and RNase A (0.02 mg/ml) for 15 minutes at 22°C.
Fluorescence was measured and analyzed using a BD Bio-
sciences FACScan flow cytometer (San Diego, CA) and
Modfit Software (Topsham, ME).
siRNA knockdown of OGFr
The OGFr-targeted siRNAs (antisense:5'-uagaaacucagguu-
uggcg-3'; sense: 5'-cgccaaaccugaguuucua-3') were
designed and obtained as ready-annealed, purified duplex
probes from Ambion (Austin, TX). For transfection, 5 ×
104 cells per well were seeded in 6-well plates containing
1 ml of serum-containing media without antibiotics. In
each well, 20 nM OGFr-siRNA or control siRNA solutions
in serum-free media were added. Cells were incubated for
4 h at 37°C prior to the addition of OGF. Cultures were
incubated an additional 20 h, and then 1 ml fresh com-
plete media either lacking or containing OGF was added.
At 96 h cells were collected for computing growth. Two
independent experiments were conducted. The control
siRNAs were purchased from Ambion.
Western blot analysis
Synchronized cells (~2 × 106) from each treatment were
solubilized in 200 μl RIPA buffer (1X PBS, 10 μM IGEPAL,
1 mg/ml SDS, 5 mg/ml deoxycholic acid), containing pro-
tease and phosphatase inhibitors (2 μg/ml aprotinin, 3
mg/ml phenylmethyl sulfonyl fluoride, 1 mM sodium
orthovanidate, 1 μM okadaic acid). Total protein concen-
trations were measured using the DC protein assay kit
(Bio-Rad Laboratories, Hercules, CA). Equal amounts of
protein (40 μg) were subjected to 10% SDS-PAGE fol-
lowed by transfer of proteins onto polyvinylidene difluo-
ride (Millipore, Billerica, MA) using standard protocols.
The following antibodies were purchased from commer-
cial sources: phospho-Rb (Ser795), phospho-Rb (Ser807/
811) (Cell Signaling Technology, Beverly, MA); Cdk2, p57
(Santa Cruz Biotechnology, Santa Cruz, CA); p21, p27,
total Rb (BD PharMingen, San Diego, CA); β-actin (Clone
AC-15, Sigma-Aldrich). Membranes were probed with sec-
ondary anti-rabbit or anti-mouse horseradish peroxidase-
conjugated antibodies (GE Healthcare-Amersham Bio-
sciences, Piscataway, NJ), and developed using a chemilu-
minescence Western blotting detection system.
In order to determine equal loading of total protein sam-
ples, blots were reprobed with monoclonal antibody
against β-actin at a dilution of 1:2000. If necessary, mem-
branes were processed in stripping buffer (62.5 mM Tris-
HCl and 100 mM β-mercaptoethanol/2% SDS, pH 6.7) at
50°C before being reprobed. Means and SE were deter-
mined from 3 or more independent experiments.
Quantitation of Western blots
To quantify expression levels or kinase activity, the optical
density of each band was determined by densitometry and
analyzed by QuickOne (Bio-Rad Laboratories). Each
value was normalized to β-actin from the same blot. To
report the changes due to OGF treatment, we calculated
the fold increase by dividing the normalized value from
the OGF treated samples by the normalized value of con-
trol samples at each time point; thus, increases due to
OGF have values greater than one, and decreases due to
OGF have values less than one.
Immunoprecipitation and H1 histone kinase assay
For immunoprecipitating protein complexes, cell extracts
were prepared as follows: 2 × 106 cells per sample were
rinsed in cold PBS followed by lysis in 200 μl immunopre-
cipitation buffer (1% NP-40, 10 mM HEPES (pH 7.5),
200 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.2 mM sodium
orthovanidate, 1 mM phenylmethyl sulfonyl fluoride,, 2
mM dithiothreitol), 1X Halt™ protease inhibitor cocktail
(Pierce, Rockford, IL)). For each immunoprecipitation
reaction mixture, a total of 500 μg of protein extract was
used. To each sample, 50 μl of protein A beads (Santa
Cruz Biotechnology) were added, and incubated at 4°C
for 30 min with rotation. Beads were removed by centrif-
ugation at 14000 rpm for 15s. The lysates were then sub-
jected to immunoprecipitation using 10 μl of polyclonal
antibody against Cdk2 and incubated at 4°C for 1.5 hours
with rotation, followed by addition of 20 μl of protein A
beads as the immune complex binding agent. Samples
were further incubated at 4°C for 1 hour with rotation.
Beads were pelleted by centrifugation at 14000 rpm for
15s, washed three times with 500 μl ice-cold immunopre-
cipitation wash buffer (1% NP40, 50 mM HEPES, 150
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol), and fol-
lowed by two washes with ice-cold H1 kinase buffer (50
mM HEPES (pH 7.5), 10 mM MgCl2, 10 mM MnCl2, 1
mM dithiothreitol). Immunoprecipitates were incubated
with 10 μCi γ32P-ATP, and 1 μg of histone H1 (Roche) as
the substrate for Cdk2. After incubation for 30 min at
30°C, with occasional mixing, the reaction was stopped
by the addition of 2× sample loading buffer (Santa Cruz
Biotechnology). Proteins were separated by a 12% SDS-
PAGE gel, and the Cdk2 kinase activity pattern was visual-
ized by autoradiography of phosphorylated H1.
p21/Cdk2 assay
Cell extracts were subjected to immunoprecipitation
using antibodies against Cdk2 and protein A beads.
Immunoprecipitates were separated on a 15% SDS-PAGE
gel, and membrane blots probed with p21 antibodies
(1:100), and developed using a chemiluminescence West-
ern blotting detection system. Blots were reprobed with
Cdk2 antibody (1:200). Three independent experiments
were performed.Molecular Cancer 2008, 7:5 http://www.molecular-cancer.com/content/7/1/5
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SiRNA knockdown of p21WAF1/CIP1
The p21-targeted siRNAs were obtained from Santa Cruz
Biotechnology, and negative control siRNAs were pur-
chased from Ambion (Ambion, INC., Austin, TX). For
transfection, 2 × 105 cells per well were seeded in 6-well
plates containing 1 ml of media without antibiotics. For
each well, 1 μl of siRNA stock (20 μM) was mixed with
175 μl of serum-free media. Two μl of Oligofectamine rea-
gent (Invitrogen, Carlsbad, CA) was added to prewashed
cells in each well, making the final concentration for
siRNA approximately 20 nM. Cells were incubated for 4
hours at 37°C prior to the addition of OGF. Eighteen
hours later, 1 ml fresh complete media with or without
OGF was added to the cultures; media and OGF were
replaced daily. At the indicated time points, cells were col-
lected for growth curves or Western blotting. Three or
more independent experiments were conducted.
Statistical analysis
Values were assessed by one-way analysis of variance
(ANOVA) and Newman Keul's post multiple comparison
tests.
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